Events Partner Content Cell and Gene Therapy Manufacturing Forum Last year we told you that the cell and gene industry would be worth $9 - $14 billion by 2026. We were wrong.
Partner Content Partner Content A Run Down of Keynote Sessions for Cell & Gene Therapy 2... Cell and Gene Therapy
Partner Content Partner Content Your Exclusive Invitation from the Chair for Cell & Gene... Cell & Gene Therapy 2018 - Chair Invitation
Partner Content Partner Content Targeting Solid & Liquid Malignancies with the Same CAR Cell and Gene Therapy
Partner Content Partner Content Exclusive Speaker Interview for SMI’s Inaugural Cell & G... Speaker Interview for Cell & Gene Therapy 2018
Partner Content Partner Content Explore the latest developments in ATMPs at Cell & Gene ... Cell & Gene Therapy 2018
News Neurogene falls again on Rett gene therapy side effects Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares.
Digital Sponsored Decoding physician prescribing behaviour: A data-driven jour... Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.